| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -35.80 M USD | -14.81 M USD | -5.90 M USD | -12.01 M USD | -10.86 M USD | -9.27 M USD | -7.56 M USD | -5.50 M USD | -12.14 M USD | -15.87 M USD | -9.75 M USD | -9.26 M USD |
| Depreciation & Amortization | — | 0 USD | 7570 USD | 5143 USD | 4116 USD | 4077 USD | 5017 USD | 9016 USD | 13621 USD | 18952 USD | 148140 USD | 150489 USD |
| Stock-Based Compensation | 19.16 M USD | 1.13 M USD | 191000 USD | — | — | — | 0 USD | 190083 USD | 79589 USD | 1062 USD | 117295 USD | 651460 USD |
| Capital Expenditures | — | — | — | 2323 USD | 5252 USD | 3490 USD | 3574 USD | 7595 USD | 4537 USD | 2884 USD | 4234 USD | 9804 USD |
| Cash Flow from Investing | — | 0 USD | 2843 USD | -2323 USD | 452609 USD | 20109 USD | -1651 USD | 7.35 M USD | 3.75 M USD | 22.21 M USD | -40.93 M USD | -147038 USD |
| Cash Flow from Financing | 38.51 M USD | 99.87 M USD | 13.57 M USD | 8.55 M USD | 9.74 M USD | 10.60 M USD | 96500 USD | 8.91 M USD | 0 USD | 0 USD | 280590 USD | 66.95 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | -12.02 M USD | -10.86 M USD | -9.28 M USD | -7.56 M USD | -5.51 M USD | -12.15 M USD | -15.87 M USD | -9.75 M USD | -9.27 M USD |
Tenax Therapeutics Inc. is a pharmaceutical company focused on developing and commercializing products for the critical care market. The primary function of Tenax Therapeutics is to develop clinical-stage treatments in areas such as cardiopulmonary diseases. One of the notable features of the company is its dedication to researching and advancing therapies to address significant unmet medical needs, particularly through innovative drug development. Tenax Therapeutics has been part of the critical care segment, working on potential treatments that could have a substantial impact on patients with severe cardiovascular and pulmonary conditions. The firm's activities in novel drug formulations and clinical trials contribute to its role in the biopharmaceutical landscape, aiming to bring new hope and innovative therapies to markets with limited options. Based in the United States, Tenax Therapeutics continues to push forward in the field of healthcare, leveraging scientific research and pharmaceutical advancements to impact the lives of patients and the broader healthcare community significantly.